

For Immediate Release

Company name: DAIICHI SANKYO COMPANY, LIMITED  
Representative: Takashi Shoda, President and Representative Director  
(Code no.: 4568, First Section, Tokyo, Osaka and Nagoya Stock Exchanges)  
Please address inquiries to Toshiaki Sai, General Manager,  
Corporate Communications Department  
Telephone: +81-3-6225-1126  
<http://www.daiichisankyo.com/>

## **Daiichi Sankyo Announces Restructuring and Relocation of Subsidiary**

**Tokyo, March 16, 2009** – Daiichi Sankyo Company, Limited announced that it will restructure its subsidiary Asubio Pharma Co., Ltd. (headquarters: Tokyo, President & CEO Seiichi Yokoyama) in April 2010 as a drug discovery venture business and be relocated in October 2010 to the site of the Kobe Medical Industry Development Project in Kobe.

Asubio Pharma, formerly a pharmaceutical business division of Suntory Limited, split from the parent company, taking over all of its pharmaceutical businesses in December 2002. Asubio Pharma currently focuses on research and development.

### **Main Objectives of business restructuring**

In order to streamline the Daiichi Sankyo Group, the various rights and functions of Asubio Pharma will be restructured on April 1, 2010 and the manufacturing unit will be transferred to Daiichi Sankyo Propharma Co., Ltd. (headquarters: Chuo-ku, Tokyo). The rights and functions to be restructured include intellectual property rights, late-stage clinical development, and pharmaceutical technology research.

Asubio Pharma will continue its core drug discovery function, which covers everything from discovery of new candidate compounds to early-stage clinical development. With its unique perspective, the company will continue to expand the development pipeline as a drug discovery venture within the Daiichi Sankyo Group. After this restructuring, Asubio Pharma expects to have approximately 200 employees.

### **Relocation to Kobe Medical Industry Development Project site**

With the April 2010 restructuring of Asubio Pharma, the three separate locations of its businesses around Japan will be consolidated, maintaining the discovery core function, from discovery research to early-stage clinical development, at the Kobe Medical Industry Development Project (KMIDP) site in Kobe. The KMIDP site is a cluster of Japanese medical industry companies, including Institute of Biomedical Research and Innovation, the RIKEN Kobe Institute, and a

number of medical facilities as well as over 130 bioventures. The site allows Asubio Pharma to utilize the external network to further promote drug discovery activities.

Daiichi Sankyo believes the KMIDP site is the optimum location for Asubio Pharma to continue its cutting edge research and development activities.

#### New Location

Address: 6 Minatojima-minamimachi, Chuo-ku, Kobe, Hyogo  
Site area: Approx. 10,000 m<sup>2</sup> (total floor area of 16,000 m<sup>2</sup>)  
Building function: Research facility, office, meeting rooms  
Schedule: relocates in October, 2010

#### **About Asubio Pharma Co., Ltd.**

Head office: Akasaka 2-9-11, Minato-ku, Tokyo  
Main offices: Biomedical Research Laboratories (Mishima-gun, Osaka),  
BioPharma Center (Ohra-gun, Gunma)  
Capital: ¥11 billion (wholly-owned subsidiary of Daiichi Sankyo Co., Ltd.)  
Representative: Seiichi Yokoyama, President & CEO  
Products: SUNRYTHM<sup>®</sup>, HANP<sup>®</sup>, ADENOSCAN<sup>®</sup>, BIOPTEN<sup>®</sup>  
Sales: ¥25 billion (projection for end of March 2009)  
Employees: 320 (approximately 240 R&D, projection for end of March 2009)  
Subsidiary: Asubio Pharmaceuticals, Inc. (Rochelle Park, New Jersey, U.S.A.)  
(committed to clinical development with approximately 30 employees)  
Business areas: Research, development, manufacturing and sales of pharmaceuticals